ANDA 212919, held by Bionpharma. Amphetamine Sulfate.
As of Nov 16, 2026, ANDA 212919 (Amphetamine Sulfate), held by Bionpharma, was first approved by FDA on Nov 22, 2019, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 22, 2019 | Original application | Approved | None posted |
| Amphetamine Sulfate5MG · tablet;oral | Amphetamine Sulfate | Rx |
| Amphetamine Sulfate10MG · tablet;oral | Amphetamine Sulfate | Rx |
| Oct 13, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 25, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 22, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters